No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
PTIX Protagenic Therapeutics
- 0.9655
- -0.0145-1.48%
Trading Jun 26 11:47 ET
4.30MMarket Cap-704P/E (TTM)
0.9800High0.9195Low1.59KVolume0.9800Open0.9800Pre Close1.51KTurnover0.05%Turnover RatioLossP/E (Static)4.45MShares2.220052wk High2.02P/B3.13MFloat Cap0.679752wk Low--Dividend TTM3.24MShs Float19.5600Historical High--Div YieldTTM6.17%Amplitude0.6790Historical Low0.9550Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Express News | Protagenic Therapeutics Inc Files for Mixed Shelf Offering of up to $100 Mln- SEC Filing
Jaguar Health, Altamira Therapeutics,Erasca Among Healthcare Movers
Express News | Protagenic Therapeutics Shares Are Trading Lower. The Company Reported Safety Data From the Single Dose Portion of Its Phase 1 Trial Involving PT00114
Express News | Protagenic Therapeutics Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial
Express News | Protagenic Therapeutics' Reports Safety Data From Single Dose Portion Of Phase 1 Trial Involving PT00114
Protagenic Therapeutics' Stress-Regulating Peptide Demonstrates Exceptional Safety in Single Dose Portion of Phase I Trial, Paving the Way for Next Steps Toward Potential Breakthrough Treatments in Stress Related Neuropsychiatric Disorders
Comments
$Protagenic Therapeutics(PTIX.US$ Protagenic Therapeutics' Reports Safety Data From Single Dose Portion Of Phase 1 Trial Involving PT00114
Benzinga· 4 mins ago
No Clinically-Relevant Adverse Events Reported in Single Dose Portion, Multiple Dose Portion to Commence
Benzinga· 4 mins ago
No Clinically-Relevant Adverse Events Reported in Single Dose Portion, Multiple Dose Portion to Commence
$Protagenic Therapeutics(PTIX.US$
NEWS
Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial
NEWS
Protagenic Therapeutics Completes Enrollment in Single Dose Portion of Phase 1 of Innovative Stress Disorder Trial
$Protagenic Therapeutics(PTIX.US$ Protagenic Therapeutics Successfully Concludes Third Cohort In Single Dose Portion Of Phase 1 Trial For Stress-Related Neuropsychiatric Disorders
$Protagenic Therapeutics(PTIX.US$ What a ugly chart! It is climbing but the spread is pretty wide! Needs more liquidity ![]()
$Protagenic Therapeutics(PTIX.US$ Protagenic Therapeutics Achieves First Clinical Safety Milestone with its Novel Neuropeptide for the Potential Treatment of Stress-Related Disorders
5 MINUTES AGO, 8:30 AM EST
VIA ACCESSWIRE
5 MINUTES AGO, 8:30 AM EST
VIA ACCESSWIRE
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg